Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MTOR | P42345 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fiacitabine SCHEMBL6715038 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| Fiacitabine SCHEMBL6725815 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| Fiacitabine SCHEMBL138935 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| Fiacitabine SCHEMBL773659 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| Fiacitabine SCHEMBL3120689 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| Fiacitabine SCHEMBL15630217 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| Fiacitabine SCHEMBL16943181 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| Fiacitabine SCHEMBL138934 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| Fiacitabine SCHEMBL1984820 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| Fiacitabine SCHEMBL7464079 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160348110-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160348110-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-9453043-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9453043-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | BANK OF AMERICA, N.A. | 2015-07-30 | — | — | US | disclosed |
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | BANK OF AMERICA, N.A. | 2015-07-30 | — | — | US | disclosed |
| US-8975389-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975389-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| EP-2403863-B1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2013-08-28 | — | — | EP | disclosed |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110130440-A1 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130440-A1 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| WO-2010101951-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2009120878-A2 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20090221523-A1 | North-2'-deoxy-methanocarbathymidines as antiviral agents against poxviruses | HEALTH AND HUMAN SERVICES, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF | 2009-09-03 | — | — | US | disclosed |
| US-20090221523-A1 | North-2'-deoxy-methanocarbathymidines as antiviral agents against poxviruses | HEALTH AND HUMAN SERVICES, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | PDE2A 3096/4885ADORA3 444/4885ADORA2A 365/4885 |
| US-20110130440-A1 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | NSUN2, RNMT, RNGTT | PDE2A 3058/4885ADORA3 499/4885ADORA2A 354/4885 |
| US-20090221523-A1 | North-2'-deoxy-methanocarbathymidines as antiviral agents against poxviruses | SAMHD1, TK2, DCTD | PDE2A 1312/4885ADORA3 1441/4885ADORA2A 824/4885 |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | PDE2A 3184/4885ADORA3 484/4885ADORA2A 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.